Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy

Trial Profile

Evaluation of Cerebrospinal Fluid Concentration of Daptomycin (Cubicin) in Pediatric Patients With Gram-positive Bacterial Meningitis, Concurrently Receiving Standard Antimicrobial Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Daptomycin (Primary) ; Ceftriaxone
  • Indications Bacterial meningitis; Gram-positive infections
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 10 Dec 2015 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018 as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Planned primary completion date changed from 1 Apr 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 10 Dec 2015 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top